Cambridge Cognition Holdings PLC - Cambridge, England-based neuroscience technology - Wins new digital health contract with an unnamed "major" pharmaceutical client to provide digital assessments of mood and cognition for a depression trial. Says the contract is worth more than GBP700,000, with most of the revenue expected to be recognised in 2021. States assessments will last over a 12-month period and will be delivered on patients' mobile phones as pharmaceutical client monitors performance and wellbeing.
"We are excited to be working with another pharmaceutical company that recognises the importance of frequent objective cognitive assessments in the development of treatments for central nervous system disorders. This new contract further validates the company's strategy as again we will be configuring existing digital health solutions rather than undertaking bespoke software development," says Chief Executive Matthew Stork.
Current stock price: 56.00 pence
Year-to-date change: doubled from 28.00p at end of 2019
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Cambridge Cog (COG)